Alliance A021806 — Perioperative versus adjuvant mFOLFIRINOX for resectable pancreatic cancer

Phase 3 · Pancreatic Cancer

Population

Resectable pancreatic adenocarcinoma.

Primary Endpoint

Overall survival

Rationale

Adjuvant mFOLFIRINOX after surgery is standard for resectable pancreatic cancer, but giving chemotherapy first (perioperative) may treat micrometastases earlier and select patients who benefit from surgery. A021806 compares the two sequences.

What It Could Change

Could shift resectable pancreatic cancer to a neoadjuvant-first chemotherapy strategy.